Pfizer Announces Additional $1.5 Billion Cost-Cutting Plan on Top of Existing $4 Billion Initiative

Pfizer, Inc. has frequently made headlines in recent months due to the company's push to save $4 billion in costs by the end of this year. Now, Pfizer has announced another cost-saving measure that will last even longer. In a filing with the U.S. Securities and Exchange Commission on Wednesday, Pfizer revealed a "multi-year plan" to initiate a new round of $1.5 billion in cost reductions aimed at cutting its sales expenses.

Source of the image: Corporate announcement

This initiative is separate from the company’s previously announced $4 billion cost-cutting strategy last year. The plan is expected to include "operational efficiency, network structure changes, and product portfolio enhancements."

The company stated in the document that this measure will begin in the second quarter of 2024. Considering the complexity of manufacturing and the longer delivery time required for changes, this plan will be a multi-phase effort. The first phase of the project will primarily focus on operational efficiency, with expected savings of approximately $1.5 billion by the end of 2027, and some plans are expected to start yielding results in 2025. The one-time costs required to achieve the savings associated with the first phase of the plan are estimated to be around $1.7 billion, mainly including severance and implementation expenses. These costs will be primarily incurred this year.

Prior to this in October 2023, Pfizer announced plans to cut $3.5 billion in costs by the end of 2024. Just two months later, the pharmaceutical company planned to cut another $500 million in costs, bringing the total cuts to $4 billion. As the cost-cutting plan proceeds, Pfizer's layoffs have already impacted its operations in many locations, including Connecticut, New Jersey, Michigan, California, the UK, Ireland, and other places.

Pfizer Launches 2023 Cost-Cutting Plan Amid Sharp Decline in Demand for COVID-19 Vaccine and Antiviral Drugs

While reducing costs, Pfizer also chose to enhance efficiency by acquiring Seagen, a tumor specialist, for $43 billion, bringing its employees into its ranks. The deal was completed last December. As part of the company's integration, Pfizer decided not to proceed with Seagen’s production projects and laid off some of Seagen’s former employees in Europe.

Pfizer Executives Recently Stated at an Investor Event: With Seagen, Pfizer Plans to Launch at Least Eight Cancer Blockbuster Drugs by 2030.

References:
Corporate Announcement
FiercePharma

Editor: Baiji

Disclaimer: This article is a reprint from Yaozhi.com. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.